Type: Active biochemical process
Duration: Resolution interval (Ri) normally 2–4 weeks
Key metric: R50 = time to 50% neutrophil clearance (12–24h)
Driven by: Specialized pro-resolving mediators (SPMs)
Blocked by: NSAIDs, omega-3 deficiency, obesity
The active biochemical process that terminates acute inflammation and restores tissue Homeostasis through coordinated lipid mediator signalling. Unlike passive decay, Resolution requires enzymatic Lipid mediator class switching from pro-inflammatory eicosanoids (Prostaglandins, leukotrienes) to Specialized pro-resolving mediators (SPMs)—including Resolvins, Protectins, and Maresins—derived from Omega-3 fatty acids (EPA and DHA). This process actively stops neutrophil recruitment, promotes neutrophil apoptosis, enhances Efferocytosis (macrophage clearance of dying cells), reprograms macrophages from M1 to M2 macrophages phenotype, and initiates tissue repair.
Think of inflammation as a construction site after a gas leak emergency. Initially, fire trucks arrive (neutrophils), spray water everywhere (PGE2, LTB4), break windows for ventilation—necessary but destructive. The emergency phase is loud, chaotic, and everyone knows something's wrong (pain, swelling, redness).
Now here's the critical part: the cleanup crew doesn't just wait for the fire trucks to run out of water. Around hour 12–18, the fire chief (PGE2 itself, ironically) radios headquarters to send specialist restoration teams (15-LOX enzyme activation). These teams (Resolvins, Maresins) arrive with specific instructions: tell remaining firefighters to stand down (stop neutrophil chemotaxis via RvE1), sweep up debris (enhance Efferocytosis), repair broken windows (restore barrier function), and bring in renovation contractors (M2 macrophages for tissue regeneration).
If someone blocks the radio signal (this is what NSAIDs do—they jam COX-2), headquarters never gets the call. The fire trucks keep spraying, the site stays chaotic for weeks, and the building never gets properly restored. You get chronic inflammation—not because the fire keeps burning, but because the cleanup crew was never summoned.
The switch from demolition (inflammation) to reconstruction (resolution) is an active metabolic decision, not passive exhaustion. It requires raw materials (Omega-3 fatty acids), functioning enzymes (15-LOX, 12-LOX), and intact signalling (COX-2 repurposing rather than blocking). No omega-3 index? No cleanup crew. Take NSAIDs? Radio silence. The result: permanent construction site chaos we call chronic pain or chronic inflammation.
Resolution proceeds through sequential, enzymatically-controlled phases requiring coordinated lipid mediator synthesis, receptor activation, and cellular reprogramming:
Tissue damage → Release of DAMPs → Pattern recognition receptors (TLRs, NLRs) activation → NF-kB nuclear translocation → Upregulation of COX-2 and 5-LOX → Arachidonic acid liberation from membrane phospholipids via cytosolic Phospholipase A2 (cPLA2)
graph TD
A[Tissue Damage/Infection] --> B[DAMPs/PAMPs release]
B --> C[TLR4/TLR2 activation]
C --> D["NF-κB → nucleus"]
D --> E["COX-2 gene expression ↑"]
D --> F["5-LOX gene expression ↑"]
E --> G["AA → PGE2 + PGD2"]
F --> H["AA → LTB4"]
G --> I[Vasodilation, pain, fever]
H --> J[Neutrophil chemotaxis peak]
G -.Critical Switch Point.-> K[PGE2 upregulates 15-LOX]
K --> L["15-LOX converts EPA/DHA → SPMs"]
Early inflammatory mediators:
- COX-2: Arachidonic acid → PGE2 (binds EP2/EP4 receptors → cAMP → pain sensitization, fever)
- 5-LOX: Arachidonic acid → 5-HPETE → LTB4 (binds BLT1 → neutrophil chemotaxis, peak at 4–8h)
- LTB4 gradient establishes maximal neutrophil infiltration (T50 = 6–12h)
Critical regulatory event: PGE2 itself (acting via EP2 receptor) and IL-4 (from early regulatory signals) upregulate 15-LOX expression in neutrophils and endothelial cells. This is the master switch enabling resolution.
Simultaneously, COX-2 undergoes post-translational modifications:
- S-nitrosylation (by iNOS-derived NO)
- Aspirin acetylation (if aspirin present → aspirin-triggered Resolvins)
Modified COX-2 now converts EPA and DHA (rather than arachidonic acid) into SPM precursors.
15-LOX pathway (rate-limiting):
- EPA → 18-HEPE → RvE1, RvE2, RvE3 (E-series Resolvins)
- DHA → 17-HDHA → RvD1, RvD2, RvD3, RvD4, RvD5, RvD6 (D-series Resolvins)
- DHA → Protectin D1 (PD1, also called neuroprotectin when made in neural tissue)
12-LOX pathway:
- DHA → 14-HDHA → MaR1, MaR2 (Maresins, "macrophage mediators in resolving inflammation")
Aspirin-triggered pathway:
- Acetylated COX-2 → DHA → AT-RvD1, AT-RvD2, AT-RvD3 (more stable than non-aspirin forms)
SPM receptors and signalling cascades:
| SPM |
Receptor |
Cell Type |
Intracellular Cascade |
Effect |
| RvD1 |
ALX/FPR2 |
Neutrophils, monocytes |
Gαi → ↓cAMP → ↓PKA → stop chemotaxis |
Halt neutrophil infiltration |
| RvD1 |
GPR32 (DRV1) |
Leukocytes |
Gαi → NF-κB inhibition |
Anti-inflammatory gene program |
| RvE1 |
ChemR23 |
Macrophages, dendritic cells |
Gαi → PI3K → Akt → enhanced phagocytosis |
Promote Efferocytosis |
| RvE1 |
BLT1 (antagonist) |
Neutrophils |
Competitive inhibition of LTB4 |
Block chemotaxis signal |
| RvD2 |
GPR18 (DRV2) |
Neutrophils, macrophages |
Gαi → ↑ bacterial phagocytosis |
Enhanced pathogen clearance |
| MaR1 |
LGR6 |
Macrophages |
β-catenin stabilization |
Tissue regeneration signalling |
Neutrophil clearance mechanism:
- SPMs downregulate chemokine receptors (CXCR1, CXCR2) → neutrophils stop migrating
- SPMs promote neutrophil apoptosis (non-lytic, programmed) rather than necrosis
- Apoptotic neutrophils expose phosphatidylserine ("eat-me" signal)
- Apoptotic cells release lysophospholipids ("find-me" signals)
- M2 macrophages recognize via MerTK, TAM receptors → Efferocytosis
Macrophage phenotype switch:
- M2 macrophages clear debris and apoptotic cells (R50 = 12–24h)
- Fibroblast activation → Collagen deposition (primarily Collagen I, Collagen III)
- Angiogenesis restores vascular supply
- Epithelial/endothelial barrier restoration
- Extracellular matrix remodelling
- Resolution interval (Ri) completes at ~2–4 weeks
Resolution metrics:
- T50: Time to 50% of maximal neutrophil count (6–12h)
- R50: Time to 50% neutrophil clearance from tissue (12–24h)
- Ri: Total resolution interval (14–28 days, injury-dependent)
graph LR
A[Injury/Infection] --> B["0-12h: PGE2 + LTB4 peak"]
B --> C["8-18h: PGE2 upregulates 15-LOX"]
C --> D["12-48h: SPMs synthesized"]
D --> E[RvD1/RvE1/MaR1 signal]
E --> F[Stop neutrophil influx]
E --> G[Promote apoptosis]
E --> H[Enhance efferocytosis]
E --> I["M1 → M2 switch"]
F --> J["12-24h: R50 reached"]
G --> J
H --> K["24h-4wk: Tissue repair"]
I --> K
K --> L[Homeostasis restored]
Traditional NSAIDs (ibuprofen, naproxen, diclofenac):
- Irreversibly inhibit COX-2 → no PGE2 production
- No PGE2 → 15-LOX never upregulated → no SPM synthesis
- Inflammation peaks but never transitions to resolution phase
- Neutrophil clearance delayed 2–4x (R50 >48h instead of 12–24h)
- Chronic pain risk increases 2.5–3x (failed resolution → persistent central sensitization)
- Delayed wound healing by 30–50% (no M2 macrophages switch)
- Increased fibrosis (unresolved inflammation defaults to scarring)
Low-dose aspirin (75–100mg) is unique:
- Irreversibly acetylates COX-2 at Ser529
- Acetylated COX-2 still functions but produces aspirin-triggered Resolvins (AT-RvD1, AT-RvD2, AT-RvD3)
- These are more stable than endogenous SPMs (longer half-life)
- Result: initial PGE2 suppressed (pain relief) BUT resolution still proceeds (via AT-SPMs)
This explains aspirin's paradoxical cardioprotective effect vs. NSAID harm: aspirin supports resolution, other NSAIDs block it.
In cPNI practice, most chronic inflammatory conditions represent failed resolution rather than excessive initiation. The 5 plus 2 metamodel identifies chronic inflammation as a central node connecting metabolic, immune, and psychological dysfunction—but the mechanism is failed SPM signalling.
Conditions driven by impaired resolution:
Hunter-gatherer omega-3 index: 8–12% (optimal SPM synthesis)
Modern Western diet: 2–4% (insufficient EPA/DHA for resolution)
The omega-3:omega-6 ratio shifted from 1:1–1:2 (ancestral) to 1:15–1:20 (modern), creating systematic SPM deficiency. This represents an Evolutionary mismatch—our genome expects abundant marine/wild game DHA/EPA to execute resolution programs evolved over millions of years.
Obesity impairs resolution through multiple mechanisms:
- Adipocyte COX-2 expression → high basal PGE2 (paradoxically without triggering switch)
- Adipose tissue sequesters DHA in triglycerides (unavailable for SPM synthesis)
- Chronic low-grade inflammation desensitizes 15-LOX upregulation
- M1 macrophages predominate in adipose tissue (resolution-incompetent phenotype)
Omega-3 Index (RBC membrane EPA+DHA):
- <4%: High risk of failed resolution, cardiovascular events
- 4–8%: Intermediate (suboptimal)
- >8%: Optimal for SPM synthesis and resolution capacity
SPM plasma levels (emerging diagnostics):
- RvD1: Normal >200 pg/mL; <100 pg/mL associated with delayed healing
- RvE1: Normal >150 pg/mL; <50 pg/mL in chronic pain patients
- LTB4:RvE1 ratio: Should be <2:1 in resolving inflammation; >5:1 indicates failed resolution
Resolution timing (post-injury):
- R50 >36h: Suggests impaired resolution capacity
- Persistent pain >6 weeks: Strongly predictive of transition to chronic pain
Support resolution, don't just suppress inflammation:
-
Omega-3 fatty acids supplementation:
- EPA+DHA 2–4g/day during acute injury/surgery
- Target omega-3 index >8%
- Start 2 weeks pre-surgery if possible (build substrate reserves)
-
Avoid NSAIDs during acute inflammation:
- Allow PGE2-mediated switch (first 12–18h)
- If analgesia essential, use low-dose aspirin (supports AT-SPMs) or paracetamol/acetaminophen (doesn't block COX-2)
- Post-injury NSAIDs delay healing by 30–50% (Lancet data)
-
Ensure adequate resolution time:
- Soft tissue injuries: minimum 2–3 weeks before aggressive rehab
- Post-surgical: 4–6 weeks for full Ri
- Premature loading disrupts M2 macrophages activity → chronic pain risk
-
Address co-factors for SPM synthesis:
- Vitamin D (cofactor for 15-LOX)
- Magnesium (required for lipid enzyme function)
- Glutathione (prevents SPM oxidative degradation)
- Selenium (GPx protects SPMs from peroxidation)
-
Reduce omega-6 load:
- Minimize seed oils (linoleic acid competes with EPA/DHA for COX-2)
- Increase omega-3:omega-6 ratio toward 1:4 or better
-
Consider direct SPM supplementation (emerging):
- Pharmaceutical-grade RvE1, RvD1 in development
- Current evidence: 1–10 ng RvE1 reduces pain 40–50% in animal models
- Human trials ongoing for post-surgical pain, periodontitis
The selfish immune system prioritizes immediate threat neutralization (neutrophil recruitment, PGE2 production) over long-term tissue preservation. From an evolutionary standpoint, surviving today's infection matters more than avoiding arthritis at age 60.
However, in modern chronic sterile inflammation (obesity, psychological stress, poor diet), the immune system activates defensive programs without actual pathogens—but still requires resolution signalling to stand down. Without adequate Omega-3 fatty acids, the system gets stuck in threat mode (chronic inflammation) even when the perceived danger (high LPS, AGEs, psychological threat) is non-lethal.
This explains why Chronic Life Stress → CTRA → failed resolution: chronic cortisol desensitizes glucocorticoid receptors on immune cells, blocking the cortisol-mediated resolution signals that would normally terminate inflammation. The selfish immune system interprets this as "still under attack" and maintains inflammatory posture indefinitely.
- Resolution is an active process requiring specific lipid mediators, not passive decay of inflammation
- R50 (time to 50% neutrophil clearance) is normally 12–24 hours in healthy resolution
- Resolution interval (Ri) is typically 2–4 weeks for soft tissue injuries
- SPMs (Resolvins, Maresins, Protectins) act at picomolar to nanomolar concentrations—100–1000× more potent than Prostaglandins
- 15-LOX is the rate-limiting enzyme for SPM synthesis, upregulated by PGE2 itself (auto-regulatory switch)
- COX-2 has dual function: pro-inflammatory (PGE2 synthesis) in hours 0–12, pro-resolving (SPM precursor synthesis) in hours 12–48
- Omega-3 index <4% is associated with impaired resolution and 2–3× increased chronic pain risk
- NSAIDs block COX-2 completely → prevent both PGE2 production AND SPM synthesis → delayed healing by 30–50%
- Low-dose aspirin (75–100mg) acetylates COX-2 → produces aspirin-triggered Resolvins → supports resolution while reducing acute pain
- RvE1 reduces inflammatory pain by 40–50% without suppressing acute inflammatory response (separates analgesia from immunosuppression)
- Failed resolution is the mechanistic link from acute injury to chronic pain, chronic inflammation, and age-related diseases
- M2 macrophages phenotype switch (driven by RvD1, IL-4) is essential for Efferocytosis and tissue repair—cannot occur without SPMs
- Obesity impairs resolution by sequestering DHA in adipose triglycerides and maintaining M1 macrophages dominance
- Modern omega-6:omega-3 ratio (15–20:1) vs. ancestral (1–2:1) represents systematic Evolutionary mismatch in resolution capacity
- Chronic pain develops when resolution fails to complete within 6–8 weeks (transition to central sensitization and pain chronification)
- Specialized pro-resolving mediators (SPMs) — lipid mediators including Resolvins, Protectins, Maresins that actively drive resolution
- Resolvins — EPA- and DHA-derived SPM family; RvE1 and RvD1 are most studied for pain reduction and inflammation termination
- Protectins — DHA-derived SPMs with neuroprotective and barrier-protective functions (protectin D1/neuroprotectin)
- Maresins — macrophage-derived SPMs (MaR1, MaR2) essential for tissue regeneration and Efferocytosis
- Efferocytosis — macrophage clearance of apoptotic neutrophils; rate-limiting step in resolution, enhanced by RvD1 and MaR1
- Lipid mediator class switching — enzymatic transition from arachidonic acid-derived pro-inflammatory mediators to EPA/DHA-derived SPMs
- COX-2 — cyclooxygenase enzyme with dual role: produces PGE2 during initiation, repurposed via acetylation/nitrosylation to produce SPM precursors
- 15-LOX — lipoxygenase enzyme that is rate-limiting for SPM biosynthesis; upregulated by PGE2 during inflammatory switch
- 12-LOX — lipoxygenase converting DHA to Maresins in macrophages
- 5-LOX — lipoxygenase producing LTB4 from arachidonic acid; activity peaks early (0–12h) then declines during resolution
- Omega-3 fatty acids — EPA and DHA are obligate dietary substrates for SPM synthesis; modern deficiency impairs resolution
- EPA — eicosapentaenoic acid, 20-carbon omega-3 fatty acid precursor of E-series Resolvins (RvE1, RvE2, RvE3)
- DHA — docosahexaenoic acid, 22-carbon omega-3 fatty acid precursor of D-series Resolvins, Protectins, Maresins
- NSAIDs — non-steroidal anti-inflammatory drugs that block COX-2, preventing both PGE2 production and SPM synthesis, delaying resolution
- aspirin — unique NSAID that acetylates COX-2, enabling production of aspirin-triggered Resolvins (AT-RvD1) rather than blocking enzyme function
- PGE2 — prostaglandin E2; paradoxically both initiates inflammation (pain, fever) AND triggers resolution by upregulating 15-LOX
- LTB4 — leukotriene B4, potent neutrophil chemoattractant peaking at 4–8h; competitively inhibited by RvE1 at BLT1 receptor
- acute inflammation — initial defensive response (0–12h) that must transition to resolution phase via Lipid mediator class switching
- chronic inflammation — pathological persistence of inflammatory signalling due to failed resolution, not excessive initiation
- macrophages — central cellular orchestrators of resolution; must transition from M1 (pro-inflammatory) to M2 macrophages (pro-resolving) phenotype
- M2 macrophages — alternatively activated macrophages with high Efferocytosis capacity, producing MaR1 and tissue repair factors (TGF-beta, VEGF)
- neutrophils — first responders in acute inflammation; must undergo apoptosis (not necrosis) and be cleared via Efferocytosis for resolution
- neutrophil apoptosis — programmed cell death of neutrophils (non-inflammatory); triggered by SPMs and essential for R50 metric
- ALX/FPR2 receptor — G-protein coupled receptor binding RvD1 and lipoxin A4; signals neutrophil arrest and enhanced phagocytosis
- ChemR23 — GPCR binding RvE1; activates macrophage Efferocytosis and anti-inflammatory programs
- GPR32 (DRV1) — GPCR binding RvD1, RvD3, RvD5; mediates anti-inflammatory gene expression via NF-κB inhibition
- chronic pain — results from failed resolution of acute inflammatory injury; central sensitization becomes permanent when Ri >6–8 weeks
- wound healing — multi-phase process requiring successful resolution for transition from inflammation to proliferation/remodelling
- obesity — impairs resolution by sequestering DHA in adipose tissue and maintaining chronic M1 macrophages activation
- Aspirin-triggered resolvins — AT-RvD1, AT-RvD2, AT-RvD3 produced when aspirin-acetylated COX-2 processes DHA; more stable than endogenous SPMs
- arachidonic acid — omega-6 fatty acid and precursor of both pro-inflammatory mediators (PGE2, LTB4) and lipoxins
- omega-3 index — percentage of RBC membrane fatty acids as EPA+DHA; optimal >8% for adequate SPM synthesis capacity
- Inflammatory bowel disease — Crohn's disease and Ulcerative Colitis show impaired mucosal SPM levels and failed resolution of gut inflammation
- Rheumatoid arthritis — synovial fluid in RA patients shows high LTB4:RvD1 ratios indicating failed joint resolution
- Atherosclerosis — arterial plaque progression driven by failed resolution of vascular inflammation; RvD1 stabilizes plaques
- Depression — linked to chronic inflammation via CTRA; impaired resolution maintains inflammatory cytokine production affecting brain function
- Cortisol — initially promotes resolution via anti-inflammatory effects, but chronic stress causes glucocorticoid resistance, blocking resolution signals
- central sensitization — pain amplification in CNS that becomes irreversible if peripheral resolution fails within 6–8 weeks post-injury
- IL-6 — pro-inflammatory cytokine during initiation, but also signals 15-LOX upregulation in some contexts (pleiotropic resolution role)
- NF-kB — transcription factor driving pro-inflammatory gene expression (hours 0–12); inhibited by SPM receptor activation during resolution
- Module 1 — Foundational understanding of inflammation vs. resolution as distinct biological programs
- Module 5 — Clinical application to pain management, chronic disease prevention, and therapeutic strategies supporting resolution